Common use of Authorization of Notes Clause in Contracts

Authorization of Notes. The Company will authorize the issue and sale of $250,000,000 aggregate principal amount of its 4.29% Senior Guaranteed Notes, Series D, due March 1, 2027, (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Notes shall be substantially in the form set out in Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified.

Authorization of Notes. The Company will authorize the issue and sale of (a) $250,000,000 300,000,000 aggregate principal amount of its 4.293.24% Series A Senior Guaranteed Notes due June 10, 2029 (the “Series A Notes”) and (b) $200,000,000 aggregate principal amount of its 3.35% Series B Senior Notes due June 10, 2032 (the “Series B Notes”; and together with the Series A Notes, Series D, due March 1, 2027, (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, collectively the “Notes”). The Series A Notes and the Series B Notes shall be substantially in the form set out in Schedule 11.1(a) and Schedule 1.1(b), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section A and, for purposes of this Agreement unless otherwise specifiedAgreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of (a) $250,000,000 25,000,000 aggregate principal amount of its 4.295.12% Senior Guaranteed Notes, Series DA, due March 1November 15, 20272036 (the “Series A Notes”) and (b) $25,000,000 aggregate principal amount of its 5.76% Senior Notes, Series B, due November 15, 2055 (as amendedthe “Series B Notes” and together with the Series A Notes, restated or otherwise modified from time the “Notes”, such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Notes shall be substantially in the form forms set out in Schedule Exhibit 1-A and Exhibit 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (i) $250,000,000 150,000,000 aggregate principal amount of its 4.295.51% Senior Guaranteed Unsecured Notes, Series DA, due March 1April 28, 20272035 (the “Series A Notes”), and (as amendedii) $50,000,000 aggregate principal amount of its 5.92% Senior Unsecured Notes, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13Series B, due April 28, 2053 (the “Series B Notes”; collectively with the Series A Notes, the “Notes”). The Notes shall be substantially in the form forms set out in Schedule 1-A and Schedule 1-B, as applicable. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to A and, for purposes of this Agreement unless otherwise specifiedAgreement, the rules of construction set forth in Section 22.4 shall govern. References to a “SectionSeries” are references of Notes shall refer to a Section of this Agreement unless otherwise specifiedthe Series A Notes and the Series B Notes or all, as the context may require.

Authorization of Notes. The Company will authorize the issue and sale of $250,000,000 103,000,000 aggregate principal amount of its 4.294.90% Senior Guaranteed Secured Notes, Series D2012-A, due March 1September 13, 2027, 2022 (as amended, restated or otherwise modified the “Series 2012-A Notes”). The Series 2012-A Notes together with each Series of Additional Notes which may from time to time be issued pursuant to the provisions of Section 17 and including 2.2 are collectively referred to as the “Notes” (such term to also include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”15). The Series 2012-A Notes shall be substantially in the form set out in Schedule Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will may authorize the issue and sale from time to time on or before May 10, 2013, in one or more Series (as hereinafter defined), of up to $250,000,000 100,000,000 aggregate principal amount of its 4.29% Senior Guaranteed senior promissory notes (the “Notes, Series D, due March 1, 2027, (as amended, restated or otherwise modified from time ,” such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Notes of any Series shall be substantially in the form set out in Schedule 1Exhibit 1 to Exhibit S, with such changes therefrom, if any, as may be approved by the Purchasers of the Notes of such Series and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of $250,000,000 (a) €100,000,000 aggregate principal amount of its 4.290.98% Senior Guaranteed Notes, Series D, due March 1July 19, 20272023 (the “Series D Notes”) and (b) €200,000,000 aggregate principal amount of its 1.17% Senior Notes, Series E, due July 19, 2024 (the “Series E Notes”; the Series D Notes and the Series E Notes are hereinafter collectively referred to as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Notes shall be substantially in the form set out in Schedule Schedules 1-A and 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section A and, for purposes of this Agreement unless otherwise specifiedAgreement, the rules of construction set forth in Section 23.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of (a) $250,000,000 25,000,000 aggregate principal amount of its 4.295.30% Senior Guaranteed Notes, Series DA, due March December 1, 20272039 (the “Series A Notes”) and (b) $25,000,000 aggregate principal amount of its 5.59% Senior Notes, Series B, due December 1, 2054 (as amendedthe “Series B Notes” and together with the Series A Notes, restated or otherwise modified from time the “Notes”, such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Notes shall be substantially in the form forms set out in Schedule Exhibit 1-A and Exhibit 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (a) $250,000,000 175,000,000 aggregate principal amount of its 4.293.35% Senior Guaranteed Notes, Series DA, due March 1February 17, 20272027 (the “Series A Notes”), and (b) $75,000,000 aggregate principal amount of its 3.45% Senior Notes, Series B, due February 17, 2029 (the “Series B Notes”; the Series A Notes and the Series B Notes are hereinafter collectively referred to as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Notes shall be substantially in the form set out in Schedule 1-A and Schedule 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section A and, for purposes of this Agreement unless otherwise specifiedAgreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of (i) $250,000,000 200,000,000 aggregate principal amount of its 4.295.47% Senior Guaranteed Unsecured Notes, Series C, due July 31, 2031 (the “Series C Notes”) and (ii) $150,000,000 aggregate principal amount of its 6.03% Senior Unsecured Notes, Series D, due March 1July 31, 2027, 2036 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series D Notes”; collectively with the Series C Notes the “Notes”). The Notes shall be substantially in the form forms set out in Schedule 1-A and Schedule 1-B, as applicable. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to A and, for purposes of this Agreement unless otherwise specifiedAgreement, the rules of construction set forth in Section 22.4 shall govern. References to a “SectionSeries” are references of Notes shall refer to a Section of this Agreement unless otherwise specifiedthe Series C Notes and the Series D Notes or all, as the context may require.

Authorization of Notes. The Company will authorize the issue and sale of (i) $250,000,000 125,000,000 aggregate principal amount of its 4.295.75% Senior Guaranteed Unsecured Notes, Series DA, due March June 1, 20272032 (the “Series A Notes”) and (ii) $175,000,000 aggregate principal amount of its 6.13% Senior Unsecured Notes, Series B, due June 1, 2037 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series B Notes”; collectively with the Series A Notes the “Notes”). The Notes shall be substantially in the form forms set out in Schedule 1-A and Schedule 1-B, as applicable. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to A and, for purposes of this Agreement unless otherwise specifiedAgreement, the rules of construction set forth in Section 22.4 shall govern. References to a “SectionSeries” are references of Notes shall refer to a Section of this Agreement unless otherwise specifiedthe Series A Notes and the Series B Notes or all, as the context may require.

Authorization of Notes. The Company will authorize the issue and sale of $250,000,000 €100,000,000 aggregate principal amount of its 4.293.80% Series 2025-A Senior Guaranteed Notes due July 9, 2035 (the “Notes, Series D, due March 1, 2027, (as amended, restated or otherwise modified from time ,” such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Notes shall be substantially in the form set out in Schedule Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (i) $250,000,000 50,000,000 aggregate principal amount of its 4.292.29% Senior Guaranteed Unsecured Notes, Series DA, due March 1December 30, 20272031 (the “Series A Notes”), and (as amendedii) $100,000,000 aggregate principal amount of its 2.97% Senior Unsecured Notes, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13Series B, due December 30, 2041 (the “Series B Notes”; collectively with the Series A Notes, the “Notes”). The Notes shall be substantially in the form forms set out in Schedule 1A and Schedule 1-B, as applicable. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to A and, for purposes of this Agreement unless otherwise specifiedAgreement, the rules of construction set forth in Section 22.4 shall govern. References to a “SectionSeries” are references of Notes shall refer to a Section of this Agreement unless otherwise specifiedthe Series A Notes and the Series B Notes or all, as the context may require.

Authorization of Notes. The Company will authorize the issue and sale of (i) $250,000,000 80,000,000 aggregate principal amount of its 4.292.59% Senior Guaranteed Unsecured Notes, Series DA, due March 1July 15, 20272033 (the “Series A Notes”), and (as amendedii) $80,000,000 aggregate principal amount of its 3.14% Senior Unsecured Notes, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13Series B, due July 15, 2041 (the “Series B Notes”; collectively with the Series A Notes, the “Notes”). The Notes shall be substantially in the form forms set out in Schedule 1-A and Schedule 1-B, as applicable. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to A and, for purposes of this Agreement unless otherwise specifiedAgreement, the rules of construction set forth in Section 22.4 shall govern. References to a “SectionSeries” are references of Notes shall refer to a Section of this Agreement unless otherwise specifiedthe Series A Notes and the Series B Notes or all, as the context may require.

Authorization of Notes. The Company will authorize the issue and sale of $250,000,000 €350,000,000 aggregate principal amount of its 4.29senior notes, consisting of (a) €150,000,000 aggregate principal amount of its 3.41% Senior Guaranteed Notes, Series DA, due March 1September 28, 20272029 (the “Series A Notes”) and (b) €200,000,000 aggregate principal amount of its 3.70% Senior Notes, Series B, due September 28, 2032 (as amendedthe “Series B Notes”, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13together with the Series A Notes, the “Notes”). The Notes shall be substantially in the form set out in Schedule 1-A and Schedule 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References A and, for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern. The Series A Notes and the Series B Notes are each herein sometimes referred to as Notes of a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedseries.”

Authorization of Notes. The Company will authorize the issue and sale of (a) $250,000,000 50,000,000 aggregate principal amount of its 4.294.30% Senior Guaranteed Notes, Series DA, due March 1July 18, 20272026 (the “Series A Notes”), and (b) $200,000,000 aggregate principal amount of its 4.35% Senior Notes, Series B, due October 18, 2026 (the “Series B Notes”; the Series A Notes and the Series B Notes are hereinafter collectively referred to as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Notes shall be substantially in the form set out in Schedule 1-A and Schedule 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section A and, for purposes of this Agreement unless otherwise specifiedAgreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of (a) $250,000,000 60,000,000 aggregate principal amount of its 4.292.48% Senior Guaranteed Notes, Series DA, due March 1August 15, 20272031 (the “Series A Notes”) and (b) $40,000,000 aggregate principal amount of its 2.63% Senior Notes, Series B, due June 15, 2033 (as amendedthe “Series B Notes”, restated or otherwise modified from time together with the Series A Notes, the “Notes”, such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Notes shall be substantially in the form forms set out in Schedule Exhibit 1-A and Exhibit 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize has authorized the issue and sale of $250,000,000 50,000,000 aggregate principal amount of its 4.293.07% Senior Guaranteed Notes, Series D2021A, due March 12051 (the “Series 2021A Notes”) and $50,000,000 aggregate principal amount of its 3.10% Senior Notes, 2027Series 2021B, due 2051 (as amendedthe “Series 2021B Notes” and, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13together with the Series 2021A Notes, the “Notes”). The Series 2021A Notes shall be substantially in the form set out in Schedule 11(a) and the Series 2021B Notes shall be substantially in the form set out in Schedule 1(b). Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section A and, for purposes of this Agreement unless otherwise specifiedAgreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of (i) $250,000,000 150,000,000 aggregate principal amount of its 4.293.21% Senior Guaranteed Unsecured Notes, Series DA, due March 1April 30, 20272030 (the “Series A Notes”) and (ii) $50,000,000 aggregate principal amount of its 3.57% Senior Unsecured Notes, Series B, due April 29, 2039 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13the “Series B Notes”; collectively with the Series A Notes, the “Notes”). The Notes shall be substantially in the form set out in Schedule 1-A through Schedule 1-B, as applicable. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to A and, for purposes of this Agreement unless otherwise specifiedAgreement, the rules of construction set forth in Section 22.4 shall govern. References to a “SectionSeries” are references of Notes shall refer to a Section of this Agreement unless otherwise specifiedthe Series A Notes and the Series B Notes or all, as the context may require.